GlassScriptPhysician profile
Joel Robinette
NPI 1114597457
$1,549.92
in general payments reported to CMS, 2019-2025
20 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.15 · 2022: $19.28 · 2024: $347 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $426.67 | 2024-2025 | |
| Novo Nordisk INC | $229.27 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $218.92 | 2024-2025 | |
| Dexcom, INC. | $120.51 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $86.93 | 2022-2025 | Otezla, Repatha, Evenity |
| Vertex Pharmaceuticals Incorporated | $68.41 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $53.41 | 2024-2025 | Breztri, Airsupra |
| Edwards Lifesciences Corporation | $50.85 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $44.62 | 2024-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.23 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $34.17 | 2025 | Voquezna |
| Mylan Specialty L.P. | $33.88 | 2024 | Yupelri |
| Tolmar, INC. | $28.87 | 2024 | |
| Viatris Specialty LLC | $25.92 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.84 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $15.42 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $14.94 | 2025 | Gemtesa |
| Lundbeck LLC | $13.93 | 2024 | Rexulti |
| Csl Behring | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Robinette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.